Merck & Co.
AWARDS
NEWS
The new vaccination, dubbed VAXELIS, is indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.
Researchers at multiple companies and institutes are doggedly pursuing clinical programs so the virus can become little more than a hindrance in the future.
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
The clinical trial, which will be conducted by Xilio, will assess XTX101’s safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
JOBS
IN THE PRESS